Search Results 261-270 of 16626 for alopecia

1. A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) - Mayo Clinic

   exception of alopecia, anorexia, nausea, vomiting, and fatigue) - Significant cardiovascular disease (such as New York Heart Association Class III or IV

2. Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer - Mayo Clinic

   ... alopecia, ototoxicity and neuropathy. Patients must not be receiving any other investigational anti-cancer agents while on study. Patients must not have ...

3. Chemotherapy Combined With Immunotherapy vs Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial - Mayo Clinic

   following exceptions, which are allowed: alopecia, vitiligo, rheumatoid arthritis, psoriasis/psoriatic arthritis, Hashimoto's thyroiditis, lupus ...

4. A Study of AbGn-107 in Patients With Gastric, Colorectal, or Pancreatic Cancer - Mayo Clinic

   Any persistent, unresolved Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥2 drug-related toxicity (except alopecia, erectile impotence ...

5. A Study of ABBV-085, an Antibody Drug Conjugate, for Patients with Advanced Solid Cancer Tumors - Mayo Clinic

   Unresolved adverse events ≥ Grade 2 from prior anticancer therapy, except for alopecia; Has ongoing hemolysis; Major surgery within ≤ 28 days prior to the ...

6. Study of TBio-6517, Given Intratumorally, Alone or in Combination With Pembrolizumab, in Solid Tumors - Mayo Clinic

   Note: Except patients with ≤ Grade 2 neuropathy or any grade of alopecia. Has tumor(s) invading a major vascular structure (e.g., carotid artery) or other ...

7. A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer - Mayo Clinic

   Grade > 1 alopecia or fatigue is permitted. Participants must allow a ... alopecia) not requiring systemic treatment, or conditions not expected to ...

8. Head and neck cancers - Doctors and departments - Mayo Clinic

   ... Alopecia areata, Melasma, Vascular anomaly, Dermatitis, Morphea, Skin problems, Birthmarks, Vulvar skin disorder, Rosacea, Pigmentation disorder, Telogen ...

9. First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b - Mayo Clinic

   Resolution of all acute toxic effects of prior therapy or surgical procedures to ≤Grade 1 except alopecia, stable immune-related toxicity such as ...

10. A Study to Test Sacituzumab Govitecan Therapy in Patients with HER2-Negative Breast Cancer and Brain Metastases - Mayo Clinic

    ... alopecia and =< grade 2 neuropathy, which are allowed; Participants with a prior or concurrent malignancy whose natural history or treatment (in the opinion ...